Experimental Study On Treatment Of Human Gastric Cancer Cell Line SGC7901 With Combination Of TRAIL And Paclitaxe

Objective:Tumor necrosis factor related apoptosis-inducing ligand (TRAIL)is a death receptor ligand that can induce apoptosis in a variety of cancer cell lines, but not all cancer cells.Past studies suggested that some Chemotherapeutic drugs intensified the sensitivity of TRAIL in inducing apoptosis.In this study,we investigate the effect and potential mechanism of combined Paclitaxe with TRAIL on apoptosis of human gastric cancer cell in vitro.Methods:SGC7901cells were cultured with Paclitaxe at different concentrations(1,5,10,20,40μg/ml)and different time(12,24,36,48h), Methylhiazolyl tetrazolium(MTT) assay was used to measure the anticancer activity of Paclitaxe.The ability of TRAIL alone,aclitaxe alone and TRAIL in combination with Paclitaxe to induce apoptosis was measured by a flow cytometer.Expression of DR4,DR5, DcR1,DcR2,Caspase-8 and Bcl-2 mRNA was examined by RT-PCR.Results:The apoptosis rate of control group( group),aclitaxe group(P group),TRAIL group(T group)and combination group(T+P)in 24h was respectively 2.09%,10.65%,7.79% and 24.51%.The apoptosis rate in T+P group was significantly higher than that in C group,T group and P group(P<0.05).Before exposure to Paclitaxe,DR5 mRNA expression was low and an increased expression of DR5 was found in SGC7901 cells after treatment with Paclitaxe.Conclusion:Paclitaxe can enhance the effect of TRAIL in anticancer therapy and its mechanisms might be involved in the up-regulation of DR5 gene.